Introduction: SCLC is a lethal neuroendocrine tumor type that is highly prone to metastasis. There is an urgency to understand the mutated genes that promote SCLC, as there are no approved targeted therapies yet available. SCLC is rarely resected, limiting the number of samples available for genomic analyses of somatic mutations.
Introduction
SCLC is a highly metastatic neuroendocrine tumor that results in the deaths of more than 200,000 individuals annually worldwide. The tumor protein p53 gene (TP53) and retinoblastoma 1 gene (RB1) are tumor suppressor genes that are mutated in most SCLCs, and v-myc avian myelocytomatosis viral oncogene homolog (MYC) family members are frequently amplified.
1,2 SCLC typically arises in heavy smokers, and the first whole genome sequencing of an SCLC cell line suggested a vast smoking-induced mutational burden. 3 Additional genomic analyses of SCLC [4] [5] [6] also revealed mutations in the CREB binding protein gene (CREBBP)/E1A binding protein p300 gene (EP300) acetyltransferases, notch 1 gene (NOTCH1), and tumor protein p73 gene (TP73), among other genes, well as amplifications including SRYbox 2 gene (SOX2). Surgical resection of SCLC is rarely performed, which has limited the number of high-quality samples available for research and excluded SCLC from The Cancer Genome Atlas. We sequenced a collection of resected human SCLCs, largely from limited-stage untreated SCLCs, as well as SCLC cell lines, largely from extensive-stage SCLCs. We report a high frequency of truncating mutations in the methyltransferase lysine methyltransferase 2D gene (KMT2D [also known as MLL2 and, in some studies, MLL4]).
Materials and Methods

Exome Sequencing to Identify SCLC Mutations
All work with human tissue was approved by the Johns Hopkins Homewood Institutional Review Board (IRB) and the Fred Hutchinson Cancer Research Center IRB. Human SCLC was obtained from the Cooperative Human Tissue Network, the Alberta Tumor Bank, the Quebec Heart and Lung Institute site of the Respiratory Health Network Tissue Bank (www.tissuebank.ca), the Ontario Institute for Cancer Research, the Alliance for Clinical Trials in Oncology Lung Cancer Tissue Bank (Cancer and Leukemia Group B study 140202 [Cancer and Leukemia Group B is now part of the alliance]), and Dr. Afshin Dowlati (Case Western Reserve Medical School). Samples were collected with informed consent or, in some cases, with IRB-approved waiver of consent. Matching normal DNA was available for exome samples, either from adjacent lung tissue or blood. Features of the exome sample set and matched controls are described in Supplementary Table 1. All primary tumors used for exome analysis were frozen tumors derived from surgical resections. SCLC cell lines were obtained directly from the American Type Culture Collection (Manassas, VA) and briefly expanded before isolation of RNA and DNA for library generation. DNA was isolated after proteinase K digest and phenol chloroform extraction. The SureSelectXT Human All Exon (50 MB) Kit (Agilent Technologies, Santa Clara, CA) was used for enrichment of coding sequences from 3 mg of genomic DNA. Samples were sequenced using an Illumina HiSeq2000/2500 (Illumina, San Diego, CA) with generation of 75-base pair paired-end reads. Paired-end short reads were first aligned to the human genome reference assembly (GRCh37/hg19) by using Burrows-Wheeler Aligner, version 0.7.5a. 7 The overview of sequence alignment statistics was computed for each sample using flagstat of Samtools (v 0.1.19, http://samtools.sourceforge.net/). Unmapped reads and polymerase chain reaction (PCR) duplicates were discarded. The resulting alignment data were further processed with the best practice of the Genome Analysis Toolkit version 2.6-5 (GATK) (Broad Institute, Cambridge, MA [https://www.broadinstitute. org/gatk/]). The sequence coverage was computed for each sample using the DepthOfCoverage tool of GATK (Supplementary Table 2 ). Somatic point mutations were detected on paired normal and tumor samples using MuTect. 8 Small insertion and deletions were analyzed with the UnifiedGenotyper tool of GATK. Variants were annotated using Annovar 9 for further evaluation. Protein-altering mutations identified in exome analyses (as shown in Fig. 1 and Supplementary Table 3 ) included nonsynonymous exonic mutations as well as intronic mutations in essential splice sites that were present in the tumor but not matched normal controls.
Targeted Resequencing
For targeted resequencing, we used the TruSeq Custom Amplicon platform (Illumina). We used DesignStudio (Illumina) to design custom primers to amplify exons for key genes. Libraries prepared from 250 ng of DNA were sequenced on an Illumina MiSeq with 250-base pair paired-end sequencing. In all, 88 libraries corresponding to SCLC cell line and tumor samples were sequenced. After alignment to hg19 by using BurrowsWheeler Aligner, the GATK best practices pipeline 10 was used to call variants that were annotated using Annovar. 9 After filtering steps, including exclusion of synonymous changes and of variants present in the 1000 Genomes database, called mutations were verified by visual scanning on the Integrative Genomics Viewer (Broad Institute). We also validated the mutations shown in Figure 2 and Supplementary Table 4 (except for those in RB1 and TP53) by using PCR amplification and Sanger sequencing (as in Supplementary Fig. 1 ). For PCR validation, primers were designed to amplify genomic DNA. PCR products were migrated on 2% agarose gels to validate specificity. The PCR products were treated with USB ExoSAP-IT reagent (Affymetrix, Inc., Santa Clara, CA) according to the manufacturer's instructions, and capillary sequencing was used for mutation validation.
Western Blot Analysis
Whole-cell protein extracts were prepared in cold cell lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% sodium dodecyl sulfate, 1% Triton X-100, 0.5% sodium deoxycholate, and 5 mM ethylenediamainetetraacetic acid) supplemented with protease and phosphatase inhibitors. Proteins were resolved on sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes. For lysine methyltransferase 2D (KMT2D) immunoblots, protein extracts were resolved on 3% to 8% Tris-acetate gels and transferred overnight before probing with anti-KMT2D antibody (Bethyl Laboratories, Inc., Montgomery, TX) overnight. Actin (Santa Cruz Biotechnology, Santa Cruz, CA) served as a loading control. Histones were acid-extracted as previously described. 11 Briefly, 10 to 30 Â 10 6 cells were resuspended in 1 mL of hypotonic buffer (10 mM Tris-Cl [pH 8.0], 1 mM KCl, 1.5 mM MgCl 2 , and 1 mM dithiothreitol supplemented with protease inhibitors). The extracts were incubated at 4 C for 30 minutes, pelleted, resuspended in 0.4 N H 2 SO 4 , and rotated overnight at 4 C. The next day, samples were spun down and the supernatant containing the histones was transferred to a new 1.5-mL tube. Trichloroacetic acid (33% final) was added drop by drop and samples were mixed by inverting. Samples were incubated on ice for 30 minutes, and the histones were pelleted by centrifugation, washed twice with icecold acetone, dried, and dissolved in water. Histones (1.5mg) were resolved on 4% to 20% Tris-glycine gels. The transferred histones were stained with Ponceau S solution as a quality check. The antibodies H3K4me1 (Millipore, Bedford, MA) and H3K4me2 (Abcam, Cambridge, MA) were used to detect histone modifications. Membranes were first probed with antibodies detecting histone modifications, then stripped with Restore Plus Western blot stripping buffer (Fisher Thermo Scientific, Waltham, MA), and finally probed for total H3 (Cell Signaling Technology, Danvers, MA). 
Results
Mutations in SCLC Exomes
We performed whole exome sequencing on 18 primary SCLCs along with matched normal lung or blood DNA (Supplementary Table 1 ). The primary tumors included 17 with classical SCLC histologic features and one with mixed SCLC/large cell histologic features (Supplementary Table 1 ). We also sequenced seven pairs of SCLC cell lines (NCI-H128, NCI-H2141, NCI-H2171, NCI-H1672, NCI-H1184, NCI-H2107, and NCI-H2195) along with matched Epstein-Barr virus-transformed lymphoblast cells derived from the same patients. We used the SureSelect 50MB (Agilent) exon capture system with massively parallel sequencing (Illumina HiSeq, Illumina). We sequenced 91% of the SCLC exome to at least 10-fold coverage, and 83% of the SCLC exome was sequenced to at least 20Â coverage (Supplementary Table 2 ). Filtering for variants that were absent in the germline, removing synonymous changes, and removing variants present in the 1000 Genomes database resulted in the detection of a median of 283 protein-altering mutations in cell lines and 224 in tumors (Fig. 1A and Supplementary Table 3 ). We note that the cell lines were from extensive-stage SCLC, whereas the frozen SCLC resections were from limited-stage SCLC; this difference could potentially contribute to an increased mutational burden in SCLC cell lines versus in SCLC surgical resections. We found that C:G>A:T transversions and C:G>T:A transitions were the most prevalent alterations in cell lines and primary tumors (Fig. 1B) . These alterations have been associated with carcinogens from tobacco smoke. 12 The most frequently mutated SCLC genes in the exome analyses were RB1 (18 of 25) and TP53 (21 of 25) (Fig. 1C) , which is consistent with the known 
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Frequent KMT2D Mutation in Human SCLCroles for these tumor suppressors in SCLC. 2 The RB1 mutations included insertions/deletions, nonsense, and essential splice site mutations. In contrast, the TP53 mutations were typically missense mutations (see Fig. 1C ).
Human SCLC Mutations beyond RB1 and TP53
We also noticed additional recurrently mutated genes beyond RB1 and TP53 (see Fig. 1C and Supplementary  Table 3 ). Focusing on genes in our exome data that harbored multiple truncating mutations, a number of known cancer genes were recurrently mutated. NOTCH1 exhibited truncating mutations in three of 18 primary SCLCs (R938fs and splice site mutation, both A929fs and Y527X in the same sample, as well as E298X nonsense mutation). Two primary SCLC tumors harbored nonsense mutations in the KMT2D/MLL2 histone methyltransferase (G4779X and both S2590X and Q809fs in the same sample). Moreover, the cell line NCI-H2171 harbored a homozygous point mutation in exon 51 of KMT2D, leading to an I5430M substitution. This mutation is within the SET domain, a conserved domain critical for methyltransferase activity. Also, we found truncating mutations in polybromo 1 gene (PBRM1), a chromatin-remodeling gene, in a primary tumor (V1011fs), and in the cell line NCI H2195 (K912fs). PBRM1 encodes the BAF180 protein (also known as polybromo 1 [PBRM1]), a bromodomain containing protein and component of the PBAF SWI/SNF chromatin-remodeling complex. This gene is located at 3p21, a region of frequent deletion in SCLC. Thus, these data indicate that chromatin modulators are likely to play major roles as tumor suppressor genes in SCLC.
SCLC Resequencing Analysis
We next took a targeted resequencing approach using the Illumina TruSeq Custom Amplicon platform to comprehensively sequence a key set of genes across 40 SCLC tumors and 48 cell lines (Supplementary Table 1) . We chose 23 genes for resequencing analysis, including those mutated in our exome set, such as KMT2D and NOTCH1, as well as genes found to be mutated in previously published SCLC genomic studies. 4, 5 We also included the lysine methyltransferase 2C gene (KMT2C), which shares homology with KMT2D, and included KMT2A/MLL, which was found mutated in another SCLC data set. 4 Again, TP53 and RB1 were the most frequently mutated genes, but we also found a striking rate of mutations in KMT2D and NOTCH1 (Fig. 2 and Supplementary Table 4 ). To more comprehensively evaluate KMT2D for mutations given incomplete coverage in the resequencing analysis, we also mined RNA-Seq data that we generated from SCLC cell lines. We found examples of expressed nonsense or frameshift KMT2D mutations in two additional lines, NCI-H446 and NCI-H2195, with mutations validated by using Sanger sequencing of genomic DNA (Supplementary Fig. 1 ). Our resequencing analysis revealed truncating mutations in many chromatin-regulating genes beyond the CREBBP and EP300 acetyltransferases that have already been well described in SCLC (Figs. 2 and 3 ). For example, we found truncating mutations in lysine demethylase 6A gene (KDM6A)/UTX, a histone demethylase found in the same protein complex as KMT2D (see Figs. 2 and 3) . We found mutations in PBRM1, and other adenosine triphosphate-dependent SWI-SNF complex members, such as AT-rich interaction domain 1 gene (ARID1A) and AT-rich interaction domain 1B gene (ARID1B). Mutations were also found in chromodomain helicase DNA binding protein 7 gene (CHD7), a gene whose protein product interacts with the PBRM1-containing PBAF complex. 13 Thus, chromatin-modifying genes are frequently mutated in SCLC.
As there has been little study of KMT2D mutations in SCLC, we examined KMT2D protein levels in SCLC cell lines with wild-type KMT2D and either hemizygous or homozygous truncating mutations (Fig. 4A) . Western blot analysis showed that mutation in KMT2D led to loss of protein expression. Very strong loss of expression was found in cell lines with homozygous KMT2D mutation and some lines harboring hemizygous mutation (see Fig. 4A ). KMT2D has been reported to confer monomethylation and dimethylation of histone H3 and lysine 4, 14, 15 with monomethylation of H3K4 being a chromatin mark associated with transcriptional enhancers. 16 We next examined whether mutation in KMT2D correlates with histone H3K4 methylation status in SCLC cell lines. Western blot analysis of extracted histones showed that KMT2D mutation in SCLC cell lines correlated with global reduction in H3K4 monomethylation and with a trend toward reduced H3K4 dimethylation (Fig. 4B) .
Discussion
We report frequent genetic alterations in chromatin regulators in SCLC. Most striking was the high frequency of truncating KMT2D mutations in our data set, which were found in 17% of SCLC cell lines and 8% of SCLC tumors. Although truncating KMT2D mutations were occasionally homozygous, most were hemizygous, suggesting that decreased gene dosage may contribute to SCLC. Although we focused on truncating mutations, some of the missense mutations in KMT2D from our study and other SCLC data sets may also be functionally important, as has been shown with a subset of KMT2D missense mutations found in lymphoma. 17 For example, the SCLC cell line H2171 harbors a homozygous I5430M mutation in the catalytic SET methyltransferase domain that is likely to be functionally important. Inactivating KMT2D mutations have been reported in approximately 90% of follicular lymphomas, 18 approximately 27% of bladder urothelial cancer, 19 medulloblastoma, 20 prostate cancer, 21 and squamous cell lung cancer, 22 among many other cancer types. Truncating mutations are found at a much lower rate in lung adenocarcinoma. 23 Inactivation of Kmt2d in mice accelerates tumorigenesis in sensitized models of B-cell lymphoma, indicating that Kmt2d functions as a bona fide tumor suppressor gene. 17, 24 KMT2D exhibits methyltransferase activity toward histone H3 lysine 4 (H3K4), specifically conferring H3K4 monomethylation and dimethylation.
14,15,25 H3K4 monomethylation is present at transcriptional enhancers and is widely used to identify both inactive and active enhancers. 16, 26, 27 Genetic loss of function studies have shown that disruption of Kmt2d or its Drosophila homologue (Trr) impairs transcriptional enhancer function. 14, 15 Despite the emergence of KMT2D as a major cancer-mutated gene, how KMT2D loss contributes to tumorigenesis is unclear. We found that SCLC cell lines harboring KMT2D mutation exhibited reduced H3K4 monomethylation, as has been found in other KMT2D mutant cells. 15 Impaired enhancer function, as found upon Kmt2d deletion in mice 15 constitutes a potential means through which KMT2D mutation may be cancer promoting. KMT2D has been detected in a protein complex that also includes the KDM6A/UTX demethylase. 25 In our exome data set, we found a truncating KDM6A mutation in a primary SCLC and nonsense mutation in an SCLC cell line, NCI-H128 (Supplementary  Table 3 ), which confirms a previously reported result in this line.
28 KMT2D undergoes frequent hemizygous inactivating mutations in Kabuki syndrome, 29 and a smaller subset of patients with Kabuki syndrome retain wild-type KMT2D but harbor KDM6A mutation. 30 In bladder urothelial cancer, KDM6A and KMT2D mutations are both frequent and they occur in a mutually exclusive fashion. 18 Thus, KMT2D mutations and KDM6A mutations likely perturb a common pathway, with KMT2D mutated in SCLC much more frequently than KDM6A.
Despite a number of previous sequencing studies having been performed on SCLC samples, including studies also showing significant KMT2D mutation rates, [31] [32] [33] KMT2D is underappreciated as a major SCLC-mutated gene. Pleasance et al. first reported KMT2D mutation in the NCI-H209 SCLC line, 3 and Rudin et al. 5 later reported mutations in KMT2D in their exome set. However, recent reports describing whole genome sequencing of 110 SCLCs 6 and exome analysis of 99 SCLCs 34 did not highlight the presence of KMT2D/MLL2 mutations. Nonetheless, both of the underlying data sets, which are published in the supplementary information of the respective studies, revealed high frequency of KMT2D mutations. In George et al., 6 22 of 110 samples in the data set had KMT2D mutations (14 of 110 truncating); we include an Oncoprint of these data as Supplementary Figure 2 . Notably, two SCLCs from the George et al. 6 data set lacking KMT2D mutation instead harbored truncating mutations in KDM6A; thus, 16 of 110 samples (15%) had either a truncating KMT2D or KDM6A mutation. Similarly, in the data set from Jiang et al., 34 11 of 99 SCLC samples exhibited a truncating mutation in KMT2D. Filtering algorithms can exclude large genes, which can exhibit many mutations simply as a consequence of gene size. However, large gene size does not explain the high frequency of truncating mutations relative to missense mutations apparent with KMT2D in SCLC in our data set and in the supplementary data sets of both George et al., 6 and Jiang et al. 34 KMT2C is highly related to KMT2D and of similar size, but it does not exhibit frequent truncating mutations in any of the SCLC data sets. Bias toward truncating KMT2D mutations in SCLC instead suggests that there is a selective advantage to inactivating this gene. Overall, truncating mutations in KMT2D are very frequent in human SCLC.
Other chromatin-modifying enzymes were also found mutated in our SCLC data set, including PBRM1, encoding BAF-180. PBRM1 is located at 3p21, a region of frequent deletion in human SCLC. 35 PBRM1 is a specificity-determining component of the PBAF SWI/SNF complex that uses adenosine triphosphate to alter nucleosome positioning. PBRM1 is a candidate 3p21 tumor suppressor frequently mutated in renal cell carcinoma 36 and cholangiocarcinoma. 37 PBRM1 was previously investigated as a potential target of mutations in SCLC cell lines, 38 but mutations were not found in the subset of SCLC cell lines examined. Given our finding of PBRM1 nonsense and frameshift mutations in SCLC, it will be important to now reexamine PBRM1 as a potential 3p21 driver mutation in SCLC. Notably, mutations in other members of the PBAF SWI/SNF complexes are also mutated in SCLC, such as the catalytic component of the PBAF complex, BRG1 encoded by SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 gene (SMARCA4). 39, 40 Moreover, we found CHD7 mutations in SCLC. Chromodomain helicase DNA binding protein 7 was found in a PBAF-containing complex that included PBRM1 (also known as BAF180). 13 Chromodomain helicase DNA binding protein 7 has also been found localized to transcriptional enhancers with enriched DNA binding to sites of H3K4 monomethylation, the mark conferred by KMT2D. 13, 41, 42 The functional importance of these mutations and overall roles for SWI/SNF complexes in SCLC requires further investigation.
The frequency of mutations in some genes was different when SCLC cell lines were compared with SCLC tumors (see Fig. 2 ). For example, truncating KMT2D mutations were more frequent in SCLC cell lines than in tumors (see Fig. 2 ). Phosphatase and tensin homolog gene (PTEN)/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutations were also more frequent in SCLC cell lines than in primary tumors (see Fig. 2 ). In contrast, truncating NOTCH1 mutations were found more frequently in tumors than in cell lines. Notably, most SCLC cell lines studied were derived from extensive-stage SCLC, whereas the primary SCLCs were largely from limitedstage SCLC. Thus, it is possible that KMT2D and/or PTEN/PIK3CA pathway mutations may be associated with more advanced SCLC. It is also possible that certain gene mutations may influence the likelihood of cell line establishment from a tumor. Thus, it will be critical for future studies to directly compare mutation profiles in sequentially collected SCLC tumor biopsy samples (or liquid biopsy samples 43 ) to determine whether genetic alterations in KMT2D and/or the PTEN/PIK3CA pathway are associated with more advanced and/or chemoresistant SCLC.
This study highlights the high frequency of inactivating mutations in KMT2D in SCLC. We show that mutations in the KMT2D methyltransferase in SCLC cell lines are associated with global reductions in H3K4 monomethylation, a mark associated with transcriptional enhancers (see Fig. 4) . Notably, other genes associated with the activation of transcriptional enhancers (i.e., the acetyltransferases CREBBP and EP300) are frequently mutated in SCLC (see Fig. 2 ). [4] [5] [6] If KMT2D tumor suppressor function is mediated through reduced H3K4 methylation and impaired enhancer function, then therapeutic approaches might be designed to reverse this effect. Of note, an inhibitor of the H3K4 demethylase LSD1 is being tested in a clinical trial for SCLC (ClinicalTrials.gov identifier NCT02034123). Whether mutations in KMT2D influence response to inhibitors of H3K4 demethylases will be critical for future studies to determine.
